Lilly Ends Basal Insulin Peglispro Development Program
December 04, 2015 at 08:00 AM EST
Eli Lilly and Company (NYSE: LLY) today announced that it will cease development of basal insulin peglispro (BIL), a potential treatment ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.